Dilation of epicardial arteries in conscious dogs induced by angiotensin-converting enzyme inhibition with enalaprilat
- PMID: 2437401
- DOI: 10.1097/00005344-198703000-00011
Dilation of epicardial arteries in conscious dogs induced by angiotensin-converting enzyme inhibition with enalaprilat
Abstract
Vasodilators may provoke myocardial ischemia in patients with coronary heart disease. Therefore, we analyzed in conscious dogs the effect of angiotensin-converting enzyme (ACE) inhibition by enalaprilat on parameters potentially important to provocation of myocardial ischemia, such as sympathetic activity, myocardial oxygen consumption, and vascular tone in coronary conduit and resistance vessels. Under normal sodium intake (2-4 mEq/kg/day), enalaprilat (0.03 and 0.3 mg/kg i.v. during 5-min infusion with 30-min intervals, n = 8) did not modify the norepinephrine release rate into plasma (a parameter of overall sympathetic activity). The higher dosage reduced myocardial oxygen consumption (to 87 +/- 2% of control), mean arterial pressure (MAP) (to 90 +/- 1%) and coronary conduit artery tone (normalized delta diameter: +3.2 +/- 0.7%) without dilating coronary resistance vessels. Following renin-angiotensin activation by sodium deprivation (3 X 1 mg/kg furosemide plus 7 days sodium intake less than 0.2 mEq/day), enalaprilat similarly lowered myocardial oxygen consumption and reduced vascular tone both in coronary conduit (normalized delta diameter: +4.0 +/- 0.9%) and resistance vessels (delta coronary flow: +45 +/- 12%). Although MAP declined to 76 +/- 6%, heart rate and norepinephrine release rate were not modified significantly. We propose that the dilation of epicardial arteries results from a direct intramural action. Enalaprilat seems unlikely to provoke myocardial ischemia even in states with a strongly activated renin-angiotensin system.
Similar articles
-
Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1076-82. J Cardiovasc Pharmacol. 1984. PMID: 6084763
-
Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure.J Am Coll Cardiol. 1987 May;9(5):1131-8. doi: 10.1016/s0735-1097(87)80318-2. J Am Coll Cardiol. 1987. PMID: 3033043
-
Resistance to blockade by saralasin of effect of ACE inhibitors in conscious sodium-restricted dog.Am J Physiol. 1988 Nov;255(5 Pt 2):F944-52. doi: 10.1152/ajprenal.1988.255.5.F944. Am J Physiol. 1988. PMID: 2847552
-
Effects of converting enzyme inhibitors on coronary flow and myocardial ischemia.J Cardiovasc Pharmacol. 1992;19 Suppl 5:S134-9. J Cardiovasc Pharmacol. 1992. PMID: 1381790 Review.
-
Regulation of coronary blood flow during exercise.Physiol Rev. 2008 Jul;88(3):1009-86. doi: 10.1152/physrev.00045.2006. Physiol Rev. 2008. PMID: 18626066 Review.
Cited by
-
The renin-angiotensin system and coronary vasomotion.Heart. 1996 Nov;76(3 Suppl 3):45-52. doi: 10.1136/hrt.76.3_suppl_3.45. Heart. 1996. PMID: 8977364 Free PMC article. Review. No abstract available.
-
Why are converting enzyme inhibitors vasodilators?Br J Clin Pharmacol. 1989;28 Suppl 2(Suppl 2):95S-103S; discussion 103S-104S. doi: 10.1111/j.1365-2125.1989.tb03585.x. Br J Clin Pharmacol. 1989. PMID: 2690910 Free PMC article. Review.
-
Control of coronary blood flow by autacoids.Basic Res Cardiol. 1995 Mar-Apr;90(2):125-41. doi: 10.1007/BF00789443. Basic Res Cardiol. 1995. PMID: 7544115 Review.
-
Pleiotropic effects of the acute and chronic inhibition of the renin-angiotensin system in hypertensives.J Hum Hypertens. 2014 Jun;28(6):378-83. doi: 10.1038/jhh.2013.125. Epub 2013 Nov 28. J Hum Hypertens. 2014. PMID: 24284385
MeSH terms
Substances
LinkOut - more resources
Miscellaneous